Hepcinat-lp

Trade Name: : - HEPCINAT-LP
Drug Form: - Medicine will be available in the form of Tablets
Generic Name: - The generic name is Ledipasvir + Sofosbuvir
International Trade Name: - Harvoni (Gilead Sciences, Inc.)
Manufactured by: - NATCO PHARMA LTD
Active Ingredients: - Ledipasvir 90mg and Sofosbuvir 400mg
Packing: - Pack of 28 Tablets
Hepatitis C is a viral infection that causes inflammation of the liver. Genotypes are used to identify particular strains of HCV which are based upon differences in particular regions of the viral genome. HARVONI (Gilead Sciences, Inc.) is a prescription medicine which contains a combination of Sofosbuvir and Ledipasvir in the dosages form of 90mg and 400 mg that is used for treatment of Chronic Hepatitis C (CHC) genotype 1 infection in adults. It is not recognized yet if HARVONI is safe and effective medicine for children under 18 years of age.
Genotype 1 HCV is the most common infection accounting for 70 to 75% of the entirely Hepatitis C infections in the UNITED STATES. Ledipasvir and Sofosbuvir are antiviral medications that help to prevent hepatitis C virus (HCV) cells from multiplying in your body.
The Indian generic of HARVONI to be manufactured by NATCO PHARMA LIMITED will soon be available in INDIA under the trade name HEPCINAT-LP. This drug will also have similar effects as HARVONI in treating Chronic Hepatitis C (CHC) genotype 1 infection in adults. The recommended dosage of Hepcinat-LP is one tablet taken orally once daily with or without food.